Cerebroside D, a glycoceramide compound, improves experimental colitis in mice with multiple targets against activated T lymphocytes

Toxicology and Applied Pharmacology

Volumn 263, Issue 3, 2012, Pages 296-302

  Wu, Xue Feng ^a   Wu, Xing Xin ^a   Guo, Wen Jie ^a   Luo, Qiong ^a   Gu, Yan Hong ^b   Shen, Yan ^a   Tan, Ren Xiang ^a   Sun, Yang ^a   Xu, Qiang ^a  

^a NANJING UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Activated T cells; Cerebroside D; Inflammatory bowel disease

Indexed keywords

CASPASE 12; CASPASE 3; CASPASE 9; CD28 ANTIGEN; CD3 ANTIBODY; CEREBROSIDE; CEREBROSIDE D; CONCANAVALIN A; CYCLOSPORIN A; DEXTRAN SULFATE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; COLITIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; HISTOPATHOLOGY; INTESTINE; LYMPHOCYTE PROLIFERATION; MALE; MORTALITY; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; REGULATORY MECHANISM; T LYMPHOCYTE ACTIVATION; WEIGHT REDUCTION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CASPASES; CELL CYCLE; CELL PROLIFERATION; CEREBROSIDES; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-1BETA; MALE; MICE; MICE, INBRED C57BL; POLY(ADP-RIBOSE) POLYMERASES; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE; MUS;

EID: 84865424790     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.07.001     Document Type: Article

References (33)

1. Alex P., Zachos N.C., Nguyen T., Gonzales L., Chen T.E., Conklin L.S., Centola M., Li X. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm. Bowel Dis. 2009, 15:341-352.
2. Appleyard C.B., Wallace J.L. Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs. Am. J. Physiol. 1995, 269:G119-G125.
3. Atreya R., Zimmer M., Bartsch B., Waldner M.J., Atreya I., Neumann H., Hildner K., Hoffman A., Kiesslich R., Rink A.D., et al. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14 macrophages. Gastroenterology 2011, 141:2026-2038.
4. Dunkle A., He Y.W. Apoptosis and autophagy in the regulation of T lymphocyte function. Immunol. Res. 2011, 49:70-86.
5. Guri A.J., Mohapatra S.K., Horne W.T., Hontecillas R., Bassaganya-Riera J. The role of T cell PPAR gamma in mice with experimental inflammatory bowel disease. BMC Gastroenterol. 2010, 10:60.
6. Hausmann M., Leucht K., Ploner C., Kiessling S., Villunger A., Becker H., Hofmann C., Falk W., Krebs M., Kellermeier S., et al. BCL-2 modifying factor (BMF) is a central regulator of anoikis in human intestinal epithelial cells. J. Biol. Chem. 2011, 286:26533-26540.
7. Hendrickson B.A., Gokhale R., Cho J.H. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin. Microbiol. Rev. 2002, 15:79-94.
8. Ishida H. Clinical implication of IL-10 in patients with immune and inflammatory diseases. Rinsho Byori 1994, 42:843-852.
9. Kawamoto M., Matsui E., Kaneko H., Fukao T., Teramoto T., Kasahara K., Kondo N. IL-10 plays an important role as an immune-modulator in the pathogenesis of atopic diseases. Mol. Med. Rep. 2008, 1:837-842.
10. Koyama K., Akiba M., Imaizumi T., Kinoshita K., Takahashi K., Suzuki A., Yano S., Horie S., Watanabe K. Antinociceptive constituents of Auricularia polytricha. Planta Med. 2002, 68:284-285.
11. Kuhl A.A., Pawlowski N.N., Grollich K., Loddenkemper C., Zeitz M., Hoffmann J.C. Aggravation of intestinal inflammation by depletion/deficiency of gammadelta T cells in different types of IBD animal models. J. Leukoc. Biol. 2007, 81:168-175.
12. Lakatos L., Lakatos P.L. Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe?. Postgrad. Med. J. 2006, 82:332-337.
13. Liu D., Huang X., Cheng S., Tong W., Wan P., Guan Y., Zhao H. Regulation of sishen wan on Bax/Bcl-2 mRNA, Fas/FasL in colonic tissue from rats with colitis. Zhongguo Zhong Yao Za Zhi 2011, 36:3484-3488.
14. Loher F., Bauer C., Landauer N., Schmall K., Siegmund B., Lehr H.A., Dauer M., Schoenharting M., Endres S., Eigler A. The interleukin-1 beta-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation. J. Pharmacol. Exp. Ther. 2004, 308:583-590.
15. Lorenz R.G., McCracken V.J., Elson C.O. Animal models of intestinal inflammation: ineffective communication between coalition members. Springer Semin. Immunopathol. 2005, 27:233-247.
16. Luo Q., Gu Y., Zheng W., Wu X., Gong F., Gu L., Sun Y., Xu Q. Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway. Toxicol. Appl. Pharmacol. 2011, 251:130-136.
17. Mitsuyama T. Purification and characterization of cerebroside sulfatase activator. Hokkaido Igaku Zasshi 1983, 58:502-512.
18. Monteleone I., Vavassori P., Biancone L., Monteleone G., Pallone F. Immunoregulation in the gut: success and failures in human disease. Gut 2002, 50(Suppl. 3):III60-III64.
19. Neuman M.G. Signaling for inflammation and repair in inflammatory bowel disease. Rom. J. Gastroenterol. 2004, 13:309-316.
20. Neurath M.F., Finotto S., Fuss I., Boirivant M., Galle P.R., Strober W. Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. Trends Immunol. 2001, 22:21-26.
21. Peng X.D., Wu X.H., Chen L.J., Wang Z.L., Hu X.H., Song L.F., He C.M., Luo Y.F., Chen Z.Z., Jin K., et al. Inhibition of phosphoinositide 3-kinase ameliorates dextran sodium sulfate-induced colitis in mice. J. Pharmacol. Exp. Ther. 2010, 332:46-56.
22. Salim S.Y., Soderholm J.D. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm. Bowel Dis. 2011, 17:362-381.
23. Sarra M., Monteleone I., Stolfi C., Fantini M.C., Sileri P., Sica G., Tersigni R., Macdonald T.T., Pallone F., Monteleone G. Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm. Bowel Dis. 2010, 16:1332-1339.
24. Shah D., Aggarwal A., Bhatnagar A., Kiran R., Wanchu A. Association between T lymphocyte sub-sets apoptosis and peripheral blood mononuclear cells oxidative stress in systemic lupus erythematosus. Free Radic. Res. 2011, 45:559-567.
25. Siegmund B., Fantuzzi G., Rieder F., Gamboni-Robertson F., Lehr H.A., Hartmann G., Dinarello C.A., Endres S., Eigler A. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001, 281:R1264-R1273.
26. Sitrin R.D., Chan G., Dingerdissen J., DeBrosse C., Mehta R., Roberts G., Rottschaefer S., Staiger D., Valenta J., Snader K.M., et al. Isolation and structure determination of Pachybasium cerebrosides which potentiate the antifungal activity of aculeacin. J. Antibiot. (Tokyo) 1988, 41:469-480.
27. Strober W., Fuss I.J. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011, 140:1756-1767.
28. Sun Y., Wu X.X., Yin Y., Gong F.Y., Shen Y., Cai T.T., Zhou X.B., Wu X.F., Xu Q. Novel immunomodulatory properties of cirsilineol through selective inhibition of IFN-gamma signaling in a murine model of inflammatory bowel disease. Biochem. Pharmacol. 2010, 79:229-238.
29. Tan R.X., Chen J.H. The cerebrosides. Nat. Prod. Rep. 2003, 20:509-534.
30. Thomas S., Baumgart D.C. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology 2012, 20:1-18.
31. Tischner D., Gaggl I., Peschel I., Kaufmann M., Tuzlak S., Drach M., Thuille N., Villunger A., Jan Wiegers G. Defective cell death signalling along the Bcl-2 regulated apoptosis pathway compromises Treg cell development and limits their functionality in mice. J. Autoimmun. 2012, 38:59-69.
32. Villablanca E.J., Cassani B., von Andrian U.H., Mora J.R. Blocking lymphocyte localization to the gastrointestinal mucosa as a therapeutic strategy for inflammatory bowel diseases. Gastroenterology 2011, 140:1776-1784.
33. Yue J.M., Fan C.Q., Xu J., Sun H.D. Novel ceramides from the fungus Lactarium volemus. J. Nat. Prod. 2001, 64:1246-1248.